{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:32:25Z","timestamp":1778682745760,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1002\/jps.24356","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T09:07:01Z","timestamp":1422436021000},"page":"2813-2823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor"],"prefix":"10.1016","volume":"104","author":[{"given":"Kathleen W.","family":"Mosure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay O.","family":"Knipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Browning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Zhong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Phillip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Mcphee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Scola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Soars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Santone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1002\/jps.24356_bb0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"The Lancet Infect Dis"},{"issue":"1","key":"10.1002\/jps.24356_bb0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/jps.24356_bb0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatol"},{"issue":"2","key":"10.1002\/jps.24356_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004836-200003000-00005","article-title":"Hepatitis C: an update on the silent epidemic","volume":"30","author":"Sarbah","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"25","key":"10.1002\/jps.24356_bb0025","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1002\/jps.24356_bb0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1002\/jps.24356_bb0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/jps.24356_bb0040","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatol"},{"issue":"13","key":"10.1002\/jps.24356_bb0045","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1002\/jps.24356_bb0050","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1002\/jps.24356_bb0055","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterol"},{"issue":"6","key":"10.1002\/jps.24356_bb0060","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1002\/jps.24356_bb0065","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/jps.24356_bb0070","author":"Company B-MS","year":"2014"},{"issue":"5","key":"10.1002\/jps.24356_bb0075","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/jm500297k","article-title":"The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection","volume":"57","author":"Scola","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"10.1002\/jps.24356_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1002\/jps.24356_bb0085","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4155\/bio.10.25","article-title":"Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method","volume":"2","author":"Browning","year":"2010","journal-title":"Bioanalysis"},{"issue":"9","key":"10.1002\/jps.24356_bb0090","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1002\/jps.24356_bb0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0163-7258(96)00184-2","article-title":"Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data","volume":"73","author":"Iwatsubo","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1002\/jps.24356_bb0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1002\/jps.24356_bb0105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"3","key":"10.1002\/jps.24356_bb0110","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatol"},{"issue":"4","key":"10.1002\/jps.24356_bb0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1002\/jps.24356_bb0120","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(14)61323-4","article-title":"All-Oral Therapy With Daclatasvir In Combination With Asunaprevir And Bms-791325 For Treatment-Naive Patients With Chronic HCV Genotype 4 Infection","volume":"60","author":"Hassanein","year":"2014","journal-title":"J Hepatol"},{"key":"10.1002\/jps.24356_bb0125","article-title":"The effect of multiple-dose Ketoconazole and the effect of multiple-dose Rifampin on the pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir","author":"Eley","year":"2013"},{"issue":"9","key":"10.1002\/jps.24356_bb0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40261-014-0219-9","article-title":"The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus","volume":"34","author":"Eley","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1002\/jps.24356_bb0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1124\/dmd.106.014464","article-title":"Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo","volume":"35","author":"Soars","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jps.24356_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1099-081X(199904)20:3<137::AID-BDD165>3.0.CO;2-I","article-title":"A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods","volume":"20","author":"Mahmood","year":"1999","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"10.1002\/jps.24356_bb0145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpdd.52","article-title":"Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C","volume":"2","author":"Eley","year":"2013","journal-title":"Clinical Pharmacol Drug Dev"},{"issue":"10","key":"10.1002\/jps.24356_bb0150","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1124\/dmd.111.039842","article-title":"The impact of hepatic uptake on the pharmacokinetics of organic anions","volume":"39","author":"Gardiner","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1002\/jps.24356_bb0155","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.110.037267","article-title":"Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption","volume":"39","author":"Paine","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jps.24356_bb0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1872-034X.2009.00593.x","article-title":"Animal models for hepatitis C and related liver disease","volume":"40","author":"Koike","year":"2010","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1002\/jps.24356_bb0165","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jps.23959","article-title":"Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-605339: A Novel HCV NS3 Protease Inhibitor","volume":"103","author":"Jenkins","year":"2014","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1002\/jps.24356_bb0170","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","article-title":"Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227)","volume":"52","author":"Seiwert","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1002\/jps.24356_bb0175","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/157018009788452474","article-title":"Use of pre-clinical in vitro and in vivo pharmacokinetics for the selection of a potent hepatitis C virus protease inhibitor, Boceprevir, for clinical development","volume":"6","author":"Cheng","year":"2009","journal-title":"Lett drug des and discov"},{"issue":"5","key":"10.1002\/jps.24356_bb0180","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/jm401840s","article-title":"Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection","volume":"57","author":"Scola","year":"2014","journal-title":"J Med Chem"},{"issue":"7","key":"10.1002\/jps.24356_bb0185","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jps.20099","article-title":"Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles","volume":"93","author":"Wajima","year":"2004","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:25:26Z","timestamp":1758360326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916300612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022354916300612"],"URL":"https:\/\/doi.org\/10.1002\/jps.24356","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}